Deutsche Bank AG boosted its stake in Regeneron Pharmaceuticals by nearly 22% in Q4, now holding 539,269 shares valued at ...

New Paltz High School senior Joseph Birnbaum was named a scholar in the Regeneron Science Talent Search (STS) for his ...

Nearly 1,700 of the brightest high school students from around the world are heading to Columbus this week to compete in ISEF ...

Students from Stirling Schools across Iraq (Baghdad, Erbil, etc.) land in USA to compete at Regeneron ISEF, the world's ...

Katelyn Dunne from Loreto College, Mullingar was named winner of the ESERO Discover Space Student Award at SciFest@DkIT 2025 ...

We recently published a list of 10 Worst Blue Chip Stocks to Buy. In this article, we are going to take a look at where ...

The new plans are in addition to $21B that the drug manufacturer has already committed to U.S. research, development and ...

We recently compiled a list of the 10 Jim Cramer Stocks with Huge Upside Potential. In this article, we are going to take a ...

Despite a risk for severe side effects, pembrolizumab has a record of improving recurrence-free survival that makes it an appealing treatment for advanced melanoma.

Improvements in Scalp Itch-Numeric Rating Scale (SI-NRS) were greater in the roflumilast group than for the vehicle group, ...

Regeneron Pharmaceuticals Inc. closed 54.78% below its 52-week high of $1,211.20, which the company reached on August 27th.

The $40 billion investment will be spread across various R&D and manufacturing areas over the next five years.